Theravance Biopharma, Inc. [TBPH] - / Zymeworks Inc. merger
Theravance Biopharma, Inc. will merge with Zymeworks Inc., with the Company becoming a wholly owned subsidiary of Zymeworks upon the effective time of the merger.
Why this matters
Theravance Biopharma, Inc., a company engaged in the development and commercialization of pharmaceutical products, primarily operates within the pharmaceutical preparations industry. The company is set to merge with Zymeworks Inc., resulting in Theravance becoming a wholly owned subsidiary of Zymeworks. This merger is structured to consolidate the operations of both companies, potentially enhancing their combined capabilities in drug development and commercialization. The definitive merger agreement outlines that no license fee royalty, upfront, milestone, or other similar payments for rights to exploit applicable intellectual property are involved in this transaction.